tbuckley/cabot-search huggingface dataset:
Prognostic value of circulating tumor DNA in advanced colorectal cancer patients: Quantification of hypermethylated or mutant sequences using picoliter droplet digital PC
Authors: A. Zaanan, F. Garlan, A. Didelot, G. Perkins, N. Siauve, H. Blons, J. Taieb, V. Taly, P. Laurent-Puig
Journal: Annals of Oncology (2016)
Cytokine Production and Proliferation in Mixed Lymphocyte Culture (MLC) May Predict Donor Engraftment in Adult Recipients of Multiple Umbilical Cord Blood (UCB) Unit Transplantation.
Authors: L. R. Fanning, M. Tary-Lehmann, J. Jaroscak, P. Rubinstein, T. McCormick, A. Swick, O. Koc, H. Lazarus, W. Tse, B. Cooper, M. Finney, O. Masri, M. Kozik, Y. Haung, D. Winter, J. Banks, K. Duam-Woods, M. J. Laughlin
Journal: Blood (2004)
The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia
Authors: Kathrin Krowiorz, Razan Jammal, Stephan Emmrich, Arefeh Rouhi, Michael Heuser, Lars Bullinger, Konstanze Döhner, Lai Courteney, Tobias Maetzig, Vera Martins, Medhanie Assmelash Mulaw, Dirk Heckl, Christian M. Zwaan, Jan Stary, Andre Baruchel, Valerie De Haas, Dirk Reinhardt, Maarten Fornerod, Hartmut Döhner, Jens Ruschmann, Marry M van den Heuvel-Eibrink, R. Keith Humphries, Florian Kuchenbauer, Jan-Henning Klusmann
Journal: Blood (2015)
Copy number alterations as predictive biomarkers for response to bevacizumab in metastatic colorectal cancer
Authors: N.C. van Grieken, M. Cordes, H.M. Verheul, M. Neerincx, C. Punt, M. Koopman, G.A. Meijer, V. Murphy, A. Barat, J. Betge, M. Ebert, T. Gaiser, B. Fender, R. Klinger, S. Das, D. Smeets, D. O'Connor, D. Lambrechts, A.T. Byrne, B. Ylstra
Journal: Annals of Oncology (2016)
U.S. Inhibitor Pilot Project: Participant Characteristics and Infusion Log Adherence.
Authors: Melissa S. Creary, John M. Soucie, Connie H. Miller, W.C. Hooper, Thomas C. Abshire, Doreen B. Brettler, Paula L. Pockenstedt, Jorge DiPaola, Gita Massey, Anne T. Neff, Amy D. Shapiro, Michael D. Tarantino, Brian M. Wicklund, Donna DiMichele
Journal: Blood (2007)
Dog Leukocyte Antigen (DLA)-Identical Sibling Cord Blood Transplantation (CBT) Following Myeloablative Total Body Irradiation (TBI).
Authors: Vladimir Lesnikov, Szczepan Baran, Kraig Abrams, Alla Nikitine, Billie Hwang, Eustacia Zellmer, Shelly Heimfeld, Marina Lesnikova, George E. Georges
Journal: Blood (2006)
Phase II randomised clinical study of metformin plus chemotherapy vs chemotherapy alone in HER2 negative metastatic breast cancer: final results of the MYME trial
Authors: A. Gennari, O. Nanni, A. Rocca, A. De Censi, A. Fieschi, A. Bologna, L. Gianni, F. Rosetti, L. Amaducci, L. Cavanna, F. Foca, S. Sarti, P. Serra, L. Valmorri, D. Corradengo, G. Antonucci, P. Bruzzi, D. Amadori
Journal: Annals of Oncology (2016)
QLIF-15. FIRST SWISS INTEGRATED MULTIDISCIPLINARY NEUROREHABILITATION PROGRAM FOR NEURO-ONCOLOGIC IN-PATIENTS
Authors: Andreas Hottinger, Bianca Moura, Cristina Pellet, Marc Levivier, Loric Berney, Massimo Giannelli, Jean-Paul Robert, Karin Diserens
Journal: Neuro-Oncology (2016)

Patients diagnosed with brain tumors are wrongly considered poor candidates for neuro-rehabilitation (NR), due to the perception of poor prognosis and the need of oncologic care following surgery. However, intensive rehabilitation often allows to improve functional independence. In this context, we have identified a need for an integrated management of neuro-oncologic patients who are not sufficiently independent to return home after neurosurgery and we set up the first Swiss neuro-rehabilitation program for neuro-oncologic patients. It is based on an innovative public-private partnership between the CHUV University Hospital and the Clinic La Lignière (LL). The later reserves beds exclusively for neuro-oncologic patients to allow the fastest transfer possible after surgical intervention. These patients benefit from acute neuro-rehabilitation in the period between intervention and early cancer adjuvant treatments (starting typically 3-5 weeks after surgery). Potential candidates are identified during their stay in neurosurgery, based on their NR potential (physiotherapy, occupational therapy, speech therapy, neuropsychology), prognosis and further treatment plan of their cancer. NR support starts early at the CHUV. Once stable, patients are transferred to LL. A referent nurse coordinates the program and ensures its flow. The first 12 months of implementation show an improvement in the management of patients on several points: 1) Improved integrated rehabilitation care and implementation of common index measures. 2) Improved patient outcome (Barthel Index and MIF improved by an average of ≥ 33%) and 75% of patients returning home. 3) Improved management of patients with a strong anchor between the nurse who accompanies the patients and their families throughout their journey, coordinates the different actors in the management and organizes the return to the primary hospital for oncological treatments. 4) Improved economic efficiency, since transferring to LL reduced the length of hospitalization of the patients at the specialized primary hospital by over 25%.
Analysis of Serial Body Height Measurements In Total Therapy 2 (TT2, Control v Thalidomide Arm) and Total Therapy 3 (A: VTD Maintenance; B: VRD Maintenance) as a Guide to Overall Bone Health In Multiple Myeloma (MM)
Authors: Alan Mitchell, Antje Hoering, Frits van Rhee, Elias J. Anaissie, John Crowley, Bart Barlogie
Journal: Blood (2010)
Evaluation of Exercise Capacity In Children with SCD by Six Minute Walk Test
Authors: Caterina Minniti, Shoaib Alam, Gregory J. Kato, Mehdi Nouraie, Craig Sable, Gregory Ensing, Andrew Campbell, Sohail Rana, Deepika Darbari, Mark Gladwin, Oswaldo Castro, Victor R. Gordeuk
Journal: Blood (2010)
Whole Genome Scanning in Aplastic Anemia Indicates That Polymorphisms in CD33 and Other Loci Can Constitute Predisposition Factors in This Disease
Authors: Bartlomiej P Przychodzen, Monika Jasek, Sandra P Smieszek, Anna Malgorzata Jankowska, Christine O’Keefe, Ronald Paquette, Jaroslaw P. Maciejewski
Journal: Blood (2008)
Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients
Authors: Michael Lübbert, Olga Grishina, Claudia Schmoor, Richard F. Schlenk, Edgar Jost, Jürgen Krauter, Michael Heuser, Felicitas Thol, Marcus M. Schittenhelm, Helmut R. Salih, Andrea Kündgen, Ulrich Germing, Katharina Götze, Hans-Walter Lindemann, Carsten Müller-Tidow, Gerhard Heil, Gesine Bug, Carsten Schwänen, Aristoteles Giagounidis, Sebastian Scholl, Andreas Neubauer, Wolfram Brugger, Maike de Wit, Sebastian Schroll, Stephan Kremers, Elisabeth Lange, Johannes Kullmer, Dirk Behringer, Matthias Egger, Irmgard Dresel, Tobias Dechow, Dietger Niederwieser, Maxi Wass, Annette M. May, Ralph Wäsch, Konstanze Döhner, Arnold Ganser, Björn Hackanson, Hartmut Döhner
Journal: Blood (2016)
GENT-23. MOLECULAR PATHOLOGICAL ANALYSIS ON IDH-WILDTYPE ADULT LOW-GRADE GLIOMAS
Authors: Akitake Mukasa, Koki Aihara, Genta Nagae, Junji Shibahara, Shota Tanaka, Shunsaku Takayanagi, Masashi Nomura, Motoo Nagane, Yoshitaka Narita, Keisuke Ueki, Ryo Nishikawa, Hiroyuki Aburatani, Nobuhito Saito
Journal: Neuro-Oncology (2016)

More than 90% of adult diffuse low-grade glioma have the IDH1/2 mutation. Diffuse astrocytoma, IDH-mutants also often harbor TP53 and ATRX mutation and oligodendroglioma have 1p/19q co-deletion. In contrast, diffuse gliomas lacking IDH mutation are rare and their molecular pathological features are not well understood. Therefore, to reveal the clinical and molecular characteristics of IDH-wildtype adult low-grade glioma, we applied multi-omics analysis to these tumors. IDH-wildtype diffuse gliomas and corresponding normal peripheral blood cells were collected from five neurosurgical facilities. Initial pathological diagnoses were made by the neuropathologist at each hospital. A few of these tumors that were detected to have IDH mutation by exome sequencing were excluded and further analyses using Illumina Infinium 450K array and RNA-sequencing were performed on the remaining 18 cases. Among these 18 cases, consensus diagnoses made by senior neuro-pathologists suggested that three cases that had KRAS, BRAF or NF1 mutation were pilocytic astrocytomas, one case with H3F3AK27M mutation was glioblastoma, and three case that had mutations in genes related to the EGFR/PI3K/PTEN signaling pathway were high-grade gliomas. All the remaining 10 tumors were from adult patients older than 20-years of age. The numbers of non-synonymous mutations in these cases varied (median 9, 0-56). The clinical features of these patients also varied greatly; some patients demonstrated a favorable prognosis with Gr.II low-grade gliomas, while other patients died within two years as do most patients with Gr.IV glioblastomas. The methylome analysis showed that these tumors had a similar methylation profile to that of mesenchymal-type glioblastoma. RNA-sequence did not detect any oncogenic fusion gene. In conclusion, IDH-wildtype diffuse gliomas seem to be a heterogeneous tumor group and their clinical courses are difficult to predict. Further molecular stratification of these tumors with advanced analytical modalities is needed.
Three-arm randomized phase II study of cisplatin and etoposide (CE) versus CE with either vismodegib (V) or cixutumumab (Cx) for patients with extensive stage-small cell lung cancer (ES-SCLC) (ECOG 1508).
Authors: Chandra Prakash Belani, Suzanne Eleanor Dahlberg, Charles M. Rudin, Martin Fleisher, Helen X. Chen, Naoko Takebe, Suresh S Ramalingam, Joan H. Schiller
Journal: Journal of Clinical Oncology (2013)

7508 Background: Targeted inhibition of the Hedgehog (HH) pathway by V &amp; Insulin-like Growth Factor type-1 Receptor (IGF-1R) by Cx enhances efficacy of chemotherapy, and also demonstrates activity against the tumor cell fraction responsible for disease recurrence in SCLC. Methods: Patients (Pts) with newly diagnosed ES-SCLC with measurable disease, ECOG PS 0-1 were randomized to receive (four 21-day cycles) CE alone [(C 75 mg/m 2 D1 &amp; E 100 mg/m 2 D1-3) Arm A] or in combination with either V [(150 mg/day PO) Arm B] or Cx [(6mg/kg weekly IV) Arm C]. Pts with responsive or stable disease on Arms B &amp; C were continued on V or Cx respectively until disease progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS), stratified on gender. Circulating tumor cells (CTCs) were isolated/enumerated by Veridex Cell Search Platform at baseline, after 1or 2 cycles of chemotherapy, at completion of 4 cycles &amp; 3 months (m). thereafter for correlation with efficacy parameters. The study was designed to detect a PFS HR of 0.58 with 90% power &amp; an overall one-sided type I error rate of 0.10 for each of the comparisons of the V and Cx arms to CE alone. Results: 155 eligible pts were treated; 136 have died &amp; 149 have experienced a PFS event. Pt. demographics &amp; disease characteristics are well-balanced between the three arms except higher rate of PS 0 on Arm B (p=0.03). The median PFS on Arms A, B &amp; C are 4.7, 4.4 &amp; 4.6 m, the median OS 9.1, 9.8 &amp; 10.1 m, &amp; the RR are 43%, 52% &amp; 49% respectively. None of the comparisons of these outcomes are statistically significant. PFS HR for V+CE vs. CE: 1.32, p=0.21, and for Cx+CE vs. CE: 1.12, p=0.58. The median OS among those with low CTC count (≤100 per 7.5ml) at baseline is 10.7 m vs. 7.2 m for those with high CTC count [HR1.70, p=0.01]. Toxicities in all three arms are as expected with the combination of CE alone. Conclusions: There is no significant improvement in PFS or OS with the addition of either V or Cx to CE vs.CE alone in pts with ED-SCLC. Low baseline CTC count is associated with improved OS, suggesting its role as a prognostic biomarker in SCLC. Clinical trial information: NCT00887159.
Do vitamin D supplements help prevent respiratory tract infections?
Authors: Mark J Bolland, Alison Avenell
Journal: BMJ (2017)

A clinically useful effect remains uncertain despite hints in a new analysis

Vitamin D supplementation is a hot topic, provoking passionate arguments for and against widespread supplementation. Recently in The BMJ we discussed the evidence, concluding that vitamin D supplements should not be taken by adults to prevent non-musculoskeletal disease.1 Three months later comes a meta-analysis by Martineau and colleagues (doi:10.1136/bmj.i6583), concluding that prevention of acute respiratory tract infection is a “major new indication for vitamin D supplementation.”2 Given the short time between articles, why are the conclusions so different? Is this really a major new development, providing the long sought reliable evidence of benefits of vitamin D on a non-skeletal outcome in the general population? Or is it yet another hypothesis about vitamin D supplementation that needs testing in adequately powered randomised controlled trials?

Eight trial level meta-analyses have examined this topic since 2012, with conflicting findings: three reported benefits and five no consistent …
Effect of nicotine on chemoresistant phenotype as mediated through Src-dependent Id1 expression in pancreatic adenocarcinoma cells.
Authors: J. G. Trevino, S. R. Pillai, S. P. Chellappan
Journal: Journal of Clinical Oncology (2011)

216 Background: The signaling pathways contributing to DNA-binding protein inhibitor Id1 expression and chemoresistance in pancreatic cancer remain unknown. Id1 plays a role in pancreatic tumor progression with tumor-promoting effects of nicotine regulating protein tyrosine kinase Src activation and Id1 expression, both associated with chemoresistance in other systems. We hypothesize Id1 expression regulates chemoresistance in pancreatic cancer through a nicotine-promoting Src-dependent pathway. Methods: We probed pancreatic cancer cell lines (L3.6pl, PANC-1, Mia-PaCa-2) for innate gemcitabine chemoresistance with cell viability MTT assay and western blot analysis of PARP cleavage programmed cell death. Gemcitabine-sensitive cells were exposed to rising gemcitabine concentrations to establish a resistant subtype, L3.6pl GemRes . Protein analysis and mRNA expression were determined by western blot analysis and RT-PCR respectively. Induction of Src phosphorylation or Id1 expression was performed with nicotine (1 μM). Results: Inhibition of c-Src expression was performed with short-interfering RNA (siRNA). Nicotine-induced Src phosphorylation and Id1 expression. Inhibition of Src by siRNA resulted in decreased nicotine-induced Id1 expression. Inhibition of Src and Id1 expression by siRNA in innate or established gemcitabine resistant pancreatic cancer cells resulted in gemcitabine sensitization. To determine if nicotine contributes to gemcitabine chemoresistance, we exposed gemcitabine-sensitive cells to nicotine with subsequent exposure to gemcitabine IC 50 , 250 ng/ml, and cell viability assays confirmed a 2-fold increase in cell prolilferation and a 4.5-fold reduction in apoptosis. Further, nicotine induced phosphorylation of key signaling enzymes involved in proliferation and apoptosis, Erk1/2 and Akt respectively. Conclusions: In summary, we demonstrate that Id1, through a nicotine-promoting Src-dependent pathway, is necessary for establishment of a chemoresistant phenotype in pancreatic cancer cells. Understanding the signaling pathways involved in pancreatic tumor chemoresistance will lead to therapies resulting in improved tumor responses. No significant financial relationships to disclose.
P08.03 Erucic acid, a component of Lorenzo’s oil used in treatment of adrenoleukodystrophy, acts antineoplastic in C6 glioma cell culture
Authors: M. A. Altinoz, A. Bilir, F. H. Bolukbasi, R. Sari, Z. Yazici, I. Elmaci
Journal: Neuro-Oncology (2016)
A New Stratification System for Adult AML That Includes FLT3-ITD as a Prognostic Factor-A JALSG Study.
Authors: Yasushi Miyazaki, Hitoshi Kiyoi, Kazutaka Kuriyama, Sumihisa Honda, Kazuhiro Nishida, Masafumi Taniwaki, Hisashi Sakamaki, Shuichi Miyawaki, Shigeki Ohtake, Tomoki Naoe, Ryuzo Ohno, Masao Tomonaga
Journal: Blood (2006)
Phase I/II Trial of Bortezomib Maintenance Following Autolgous Peripheral Blood Progenitor Cell Transplantation as Treatment for Intermediate- and Advanced-Stage Multiple Myeloma.
Authors: Gary J. Schiller, J. Phillip Sohn, R. Malone, K. Bartone, B. Habtemariam, R. Paquette, Sven De Vos, M. Territo
Journal: Blood (2006)
Does low-risk prostate cancer detection change with repeat biopsies?
Authors: Bobby B. Najari, Michael Rink, Jens Hansen, Roman Heuer, Christian Eichelberg, Sascha A. Ahyai, Alexander Haese, Thomas Steuber, Hans Heinzer, Margit Fisch, Luis A. Kluth, Hartwig Huland, Markus Graefen, Douglas Scherr, Shahrokh F. Shariat, Felix K. Chun
Journal: Journal of Clinical Oncology (2012)

188 Background: Many patients with a negative prostate biopsy (PBx) but persistent clinical suspicion of prostate cancer (PCa) undergo repeat PBx. Although higher rates of low grade PCa on repeat PBx have been reported, we hypothesize that a considerable risk of clinically significant PCa remains. Methods: We retrospectively reviewed the data from a cohort of 25,584 patients who underwent one or more PBx at two institutions. To ensure current standards, we only included patients biopsied from 2004 to 2010 with a minimum of ten cores taken. Statistical analysis was performed using SPSS v.17.0. Results: 6,729 men met the inclusion criteria, 764 (11.4%) of whom underwent a second PBx after negative initial biopsy. Overall, 3669 (54.6%) men were diagnosed with PCa on first PBx whereas 199 (26.0%) had a positive second PBx (p&lt;0.01, Table 1). Cancers detected on the second PBx were more likely to be Gleason 6 than cancers detected on initial PBx (60.8% vs. 46.1%, p&lt;0.01). We further categorized men as having low risk PCa, as defined by PSA &lt;10ng/mL, Gleason sum 6, clinical stage ≤T2a, and ≤2 biopsy cores positive. The proportion of low risk patients was significantly higher in repeat PBx compared to initial PBx (36.2% vs. 23.6%, p&lt;0.01). Conclusions: Despite having a negative initial PBx, over a quarter of men who underwent a repeat biopsy in our large cohort had PCa detected. Despite the pathologic characteristics being more favorable on repeat PBx, almost two-thirds of these men still had intermediate or high-risk PCa. In conclusion, men in whom there is persistent suspicion for PCa despite a negative PBx should be counseled that repeat biopsies detect a high number of clinically significant PCa. [Table: see text]
Low-Dose Rituximab and High-Dose Dexamethasone As Front-Line Therapy in Adult Patients with Primary Immune Thrombocytopenia
Authors: David Gomez-Almaguer, Luz C. Tarin-Arzaga, Brizio Moreno-Jaime, Jose C. Jaime-Pérez, Adrián A. Ceballos-López, Guillermo J. Ruiz-Argüelles, Guillermo J. Ruiz-Delgado, Olga Cantú-Rodríguez, Cesar H Gutiérrez-Aguirre
Journal: Blood (2012)
Fludarabine Plus I-131 Tositumomab as Initial Treatment for Follicular Lymphoma: Half of Patients In Remission at Over 10 Years Median Followup.
Authors: Peter Martin, Morton Coleman, Richard R. Furman, Shankar Vallabhajosula, Dong Sun Kim, Andrew Edelstein, Julia Morrison, Rebecca Elstrom, Jia Ruan, Stanley J. Goldsmith, John P. Leonard
Journal: Blood (2010)
S-1 plus oxaliplatin combined with radiation (SOX/RT) for preoperative locally advanced rectal carcinoma: final results of a phase II study (JACCRO CC-04: SHOGUN trial)
Authors: H. Horie, S. Matsusaka, S. Ishihara, K. Kondo, K. Uehara, M. Oguchi, K. Murofushi, M. Ueno, N. Mizunuma, T. Shimbo, D. Kato, J. Okuda, Y. Hashiguchi, M. Nakazawa, E. Sunami, K. Kawai, H. Yamashita, T. Okada, T. Nakajima, T. Watanabe
Journal: Annals of Oncology (2016)
First prospective multicenter Italian study on the impact of the 21-gene recurrence score (RS) in adjuvant clinical decisions for ER+/HER2- early breast cancer (BC) patients
Authors: M.V. Dieci, V. Guarneri, T. Giarratano, M. Mion, G. Tortora, P. Morandi, S. Gori, L. Merlini, C. Oliani, F. Pasini, G. Bonciarelli, G. Griguolo, E. Orvieto, P. Del Bianco, G.L. De Salvo, P. Conte
Journal: Annals of Oncology (2017)
First steps in the definition of a prognostic score based on MGMT methylation status in patients with glioblastoma
Authors: E. De Carlo, L. Gurrieri, G. De Maglio, L. Gerratana, V. Buoro, S. Rizzato, M. Isola, M. Skrap, G. Fasola, F. Puglisi, S. Pizzolitto
Journal: Annals of Oncology (2016)
Potential of surfactant-coated nanoparticles to improve brain delivery of arylsulfatase A
Authors: Tilman Schuster, Astrid Mühlstein, Claudia Yaghootfam, Olga Maksimenko, Elena Shipulo, Svetlana Gelperina, Jörg Kreuter, Volkmar Gieselmann, Ulrich Matzner
Journal: Journal of Controlled Release (2017)
IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)
Authors: J. Bellmunt, A. Balar, M.D. Galsky, Y. Loriot, C. Theodore, E. Grande Pulido, D. Castellano, M. Retz, G. Niegisch, S. Bracarda, A. Necchi, U. Vaishampayan, S. Sridhar, B.J. Eigl, S. Hussain, M. van der Heijden, B. Danner, S. Mariathasan, F. Legrand, J.E. Rosenberg
Journal: Annals of Oncology (2016)
Phosphatidylinositol-4, 5-biphosphate 3-kinase, catalytic subunit alpha (PI3KCA) and microsatellite instability in ovarian clear cell carcinoma, clinical correlation
Authors: M. Batista, I. Romero, J.P. Molina, L. Brot, A. Costa, R. López, P. Mallol, J. Palacios, C. Illueca, C. Mendes, G. Machado, A. Santiago, E. Rego, J.A. López, A. Poveda
Journal: Annals of Oncology (2016)
Clinical utility of circulating tumor DNA (ctDNA) in resectable pancreatic ductal adenocarcinoma (PDAC)
Authors: H.-L. Wong, K. Bushell, J. Karasinska, S. Arthur, P. Pararajalingam, R. Morin, D.F. Schaeffer, D.J. Renouf
Journal: Annals of Oncology (2016)
ANGI-08. IDENTIFICATION OF NOVEL MOLECULAR PLAYERS OF GBM CELL DISPERSAL THROUGH AN IN VITRO PROFILING APPROACH
Authors: Fidan Seker, Alp Erkent, Nazlı Ergüder, Kenan Sevinç, Mehmet Gönen, Zeynep Hülya Gümüş, Tugba Bagci-Onder
Journal: Neuro-Oncology (2016)

Glioblastoma multiforme (GBM) is the most common and aggressive type of gliomas with a mean survival of 1 year after diagnosis. A major obstacle in treating GBMs is extensive tumor cell infiltration into the surrounding brain. Despite tumor resection and combined therapy, recurrence occurs in the vicinity of the resection margin due to individual cells that dispersed out of the primary tumor, therefore; developing novel therapies that target tumor cell dispersal is of high priority. The goal of this project is to identify genes that are differentially regulated during GBM cell dispersal and to validate their function in in vitro models of dispersal. In this project, we have used an in vitro model of cell motility whereby the dynamics of GBM cell dispersal can be monitored in real-time and quantitated. Accordingly, we isolated motile/migratory/dispersive cells from non-motile/core cells and used these cells for investigating the genes that are differentially regulated during different phases of cell movement by using RNA sequencing. Analysis of the sequencing experiments showed the presence of many differentially expressed genes in motile vs non-motile cells. Most of the genes that have the highest expression in motile cells compared to non-motile ones were linked to epithelial to mesenchymal transition and cell motility based on our pathway and gene set enrichment analyses. Our current focus is on five different candidate genes: CTGF, CYR61, SERPINE1, INHBA and PTX3. Among these, the expression of SERPINE1, a serine protease inhibitor, had predictive value for overall survival of gliomas and therefore is an interesting therapeutic candidate. Currently, we are conducting loss-of-function and gain-of function experiments targeting these genes. Together, these studies have the potential to discover novel molecular players of GBM cell dispersal and open up new avenues for designing new therapeutic strategies against the invasive phenotype of otherwise untreatable malignant GBMs.